Medical Devices Brazil

Brazil Polygenic Risk Scores Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Brazil Polygenic Risk Scores Market Industry Trends and Forecast to 2034: Segmented by (Condition, User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Brazil · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $4.1 Mn Placeholder estimate
Estimate 2025 $4.8 Mn 2.3% of the global market
Projected 2034 $23.7 Mn 389.5% Adds $18.8 Mn over 9 forecast years
CAGR 2025–2034 19.3% Faster than 94% of 173 Medical Devices markets here
Key players 5
  • Brazil is 2.32% of the global market.
  • In Latin America, the largest is Brazil (this report) at $4.8 Mn.
  • Fastest growing: Brazil (this report) at 19.3% a year.
  • Brazil ranks 1st of 3 by size in Latin America.

Market size projection

Brazil

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$18.8 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Polygenic Risk Scores Market market size by year, Brazil
YearMarket sizeChange that yearSince 2025
2024 (estimate) $4.1 Mn — —
2025 (base) $4.8 Mn +$0.8 Mn —
2026 (forecast) $5.8 Mn +$0.9 Mn +19.3%
2027 (forecast) $6.9 Mn +$1.1 Mn +42.3%
2028 (forecast) $8.2 Mn +$1.3 Mn +69.8%
2029 (forecast) $9.8 Mn +$1.6 Mn +102.6%
2030 (forecast) $11.7 Mn +$1.9 Mn +141.7%
2031 (forecast) $14.0 Mn +$2.3 Mn +188.3%
2032 (forecast) $16.6 Mn +$2.7 Mn +243.9%
2033 (forecast) $19.9 Mn +$3.2 Mn +310.3%
2034 (forecast) $23.7 Mn +$3.8 Mn +389.5%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Brazil Polygenic Risk Scores Market Analysis at a glance
Market size, 2025$4.8 Mn placeholder estimate
Forecast, 2034$23.7 Mn placeholder estimate
Growth (CAGR), 2025–203419.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsCondition and user (see all)
Key playersGenomics plc, Allelica, Myriad Genetics, Inc., 23andMe, Color Health (see all)
Regulator in BrazilANVISASource: ANVISA. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Brazil Polygenic Risk Scores Market Analysis Executive Summary

Polygenic risk scores combine many small genetic effects to estimate a person's risk of common diseases such as heart disease and diabetes.

Key segments of the polygenic Risk Scores market include condition (Cardiovascular Disease, Cancer and Diabetes) and user (Clinicians, Consumers and Researchers).

Bar chart: Brazil Polygenic Risk Scores market size, 2024–2034, placeholder estimates. $4.1 Mn in 2024, $4.8 Mn in 2025 and $23.7 Mn in 2034, 19.3% CAGR.
Brazil Polygenic Risk Scores market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Brazil Polygenic Risk Scores Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the polygenic Risk Scores market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the polygenic Risk Scores market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the polygenic Risk Scores market.

Competitive Landscape for Polygenic Risk Scores Market in Brazil

The polygenic Risk Scores market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Polygenic Risk Scores Market in Brazil

Polygenic Risk Scores in Brazil: rules and payment

Medical devices are notified to or registered with ANVISA, the National Health Surveillance Agency, depending on their risk class.⁠[1] The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds.⁠[2]

[1] ANVISA. Checked 14 Nov 2026.

[2] CONITEC. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how polygenic Risk Scores products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Brazil.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Polygenic Risk Scores right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Polygenic Risk Scores in context

Brazil compared

  • Health spending per person: 1,010 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 4 countries we cover in Latin America.[1]
  • Doctors: 2.36 per 1,000 people (2023). World: 1.86 per 1,000 people (2022). 2nd highest of the 4 countries we cover in Latin America.[2]
  • People aged 65 and over: 11.5% of people (2025). World: 10.4% of people (2025). Highest of the 4 countries we cover in Latin America.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Polygenic Risk Scores market in Brazil?
Placeholder estimate: about $4.8 Mn in 2025, rising to about $23.7 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Polygenic Risk Scores market in Brazil growing?
Placeholder estimate: about 19.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Polygenic Risk Scores market report cover?
The report splits the market by condition (Cardiovascular Disease, Cancer, Diabetes, Psychiatric Conditions) and user (Clinicians, Consumers, Researchers).
Who are the key players in the Polygenic Risk Scores market?
Key players include Genomics plc, Allelica, Myriad Genetics, Inc., 23andMe and Color Health.
What is driving the Polygenic Risk Scores market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the polygenic Risk Scores market.
Who regulates Polygenic Risk Scores in Brazil?
Medical devices are notified to or registered with ANVISA, the National Health Surveillance Agency, depending on their risk class. Source: ANVISA. Checked 14 Nov 2026.
How is healthcare paid for in Brazil?
The Unified Health System (SUS) gives free public care to everyone, and CONITEC advises which medicines and technologies it adds. Source: CONITEC. Checked 14 Nov 2026.
How much research is published on Polygenic Risk Scores?
PubMed lists 3,814 papers on Polygenic Risk Scores added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Brazil

See all

Related on genomics and diagnostics and lab testing

See the topic